Ergomed plc, a provider of specialized services to the pharmaceutical industry, has acquired Ashfield Pharmacovigilance Inc., a specialist pharmacovigilance services provider based in RTP, NC, from UDG Healthcare plc for $10 million in cash.

Ashfield Pharmacovigilance becomes part of Ergomed’s PrimeVigilance division, expanding its specialist pharmacovigilance business and establishing a platform for the broader Ergomed services business in the U.S. The acquisition adds more than 40 new clients to PrimeVigilance and a order book of contracted future revenues of $9.8 million. Ashfield Pharmacovigilance Inc. reported $11.6 million revenue in the year ended September 30, 2019.

Dr. Miroslav Reljanović, executive chairman of Ergomed, said, “The acquisition of Ashfield PV is a major step forward for Ergomed in the strategically important U.S. market. It provides a significant U.S. pharmacovigilance presence and access to a global offering for customers. It also strengthens the U.S. platform for the Ergomed CRO business as we continue our drive towards becoming a leading mid-tier pharmaceutical services specialist with a global presence. We are enthusiastic about bringing together the specialist skills and expertise of both businesses and providing the full benefit of the combination to our clients.”

Lee Chaiken, senior vice president and general manager of Ashfield PV, said, “We are delighted to join the PrimeVigilance business and to have the opportunity to work with the whole Ergomed group. With our existing strong service and loyal clients in North America, we are confident that combining with PrimeVigilance will provide a platform to grow the combined pharmacovigilance business through additional services, market-leading systems and extended coverage globally.”